Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06846671 · ClinicalTrials.gov registry record · Phase 3

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

A Phase 3 study of Chronic Lymphocytic Leukemia and CLL, sponsored by BeOne Medicines.

Recruiting
Registry status
Phase 3
Development phase
250
Enrollment target
20
Study locations

NCT06846671: Recruiting Phase 3 study of Chronic Lymphocytic Leukemia and CLL, sponsored by BeOne Medicines.

NCT06846671 is a Phase 3 study of Chronic Lymphocytic Leukemia and CLL that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 250 participants, above the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06846671, a Phase 3 study of Chronic Lymphocytic Leukemia and CLL, is actively recruiting participants, sponsored by BeOne Medicines.

RECRUITING
Registry status
Phase 3
Development phase
250 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).

Primary Outcome

PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL).

Conditions Studied

Chronic Lymphocytic Leukemia CLL

Interventions

  • DRUG Venetoclax
  • DRUG BGB-16673
  • DRUG Rituximab
  • DRUG Bendamustine
  • DRUG Idelalisib

Study Locations (20)

Florida

  • Florida Oncology and Hematology - Fort Myers
  • Baptist Md Anderson Cancer Center - Jacksonville
  • Cleveland Clinic Florida - Weston

California

  • UCLA Department of Medicine Hematologyoncology - Los Angeles
  • Pih Health Whittier Hospital - Whittier

New York

  • Memorial Sloan Kettering Cancer Center Mskcc - New York
  • Clinical Research Alliance, Inc - Westbury

Ohio

  • University Hospitals - Cleveland
  • Dayton Physician Network - Dayton

Pennsylvania

  • West Penn Hospital - Pittsburgh
  • Cancer Care Associates of York - York

Arkansas

  • St Bernards Medical Center - Jonesboro

Colorado

  • Rocky Mountain Cancer Centers (Williams) Usor - Aurora

Georgia

  • Emory University Winship Cancer Institute - Atlanta

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2025-04-10
Est. Completion 2030-02-14
Phase Phase 3
BeOne Medicines

29 total trials

What NCT06846671 shows while recruiting

NCT06846671 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (38% higher).

The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Venetoclax is the first listed.

NCT06846671 names 20 study sites across 14 states, led by Florida, California, New York.

Frequently Asked Questions

What is clinical trial NCT06846671 about?

NCT06846671 is a clinical study titled "A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors". The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small l...

What is the current status of trial NCT06846671?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2025-04-10. Estimated completion is 2030-02-14.

What conditions does trial NCT06846671 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, CLL.

What interventions are being tested in trial NCT06846671?

The interventions under investigation include: Venetoclax (DRUG), BGB-16673 (DRUG), Rituximab (DRUG), Bendamustine (DRUG), Idelalisib (DRUG).

Who is sponsoring clinical trial NCT06846671?

This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06846671 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06846671's enrollment target sits among peer trials

250 33rd of 187 higher than 155 of 187 other Chronic Lymphocytic Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06846671

Source: ClinicalTrials.gov NCT06846671, the US trial registry maintained by the National Library of Medicine. NCT06846671 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.